Malignant Pleural Effusions (Mpe)
Conditions
Brief summary
A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Interventions
DRUGJMKX000197
for pleural perfusion
PROCEDURETube thoracostomy drainage
Tube thoracostomy drainage
Sponsors
Jemincare
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The participant voluntarily joined the study, signed an informed consent form, and had good compliance. 2. Age ≥ 18 years and ≤ 75 years old, regardless of gender. 3. Participants with advanced solid tumors diagnosed by histopathology or cytopathology. 4. Malignant pleural effusion confirmed by histopathology or cytopathology or clinically diagnosed as moderate or above and requiring drainage. 5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 2. 6. Life expectancy of at least 3 months. 7. Adequate organ function. 8. Female participants of childbearing potential should agree to use contraception to prevent pregnancy until 6 months after discontinuation of JMKX000197. The serum pregnancy test result should be negative 7 days before enrollment and must be a non-lactating participant. Male participants must agree to use effective contraception during the study and for 6 months after discontinuation of JMKX000197.
Exclusion criteria
1. Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion. 2. Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion. 3. Have used interferon gene stimulating factor (STING) agonists for pleural perfusion。 4. Known allergies to the study drug or its excipient components. 5. Have participated in other clinical trials within 28 days prior to randomization. 6. Major surgery within 28 days prior to randomization. 7. Central nervous system metastatic disease, leptomeningeal disease, or cord compression. 8. Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases. 9. Uncontrollable systemic infections (viruses, bacteria, fungi), including but not limited to positive HBsAg and HBV DNA, positive HCV RNA, positive HIV antibody test or combined infections within the first 28 days of randomization and require systemic anti-infective treatment. 10. Have a history of organ transplantation. 11. Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AEs or SAEs | Up to approximately 36 days |
| Recommended Phase II dose (RP2D) | Up to approximately 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Puncture /drainage-Free Survival (PuFS) | Up to approximately 24 months |
| Pleural effusion overall response (ORR) | Up to approximately 24 months |
| Overall survival (OS) | Up to approximately 24 months |
| Pharmacokinetics (Cmax) | Up to approximately 7 days |
| Pharmacokinetics(Tmax) | Up to approximately 7 days |
| Pharmacokinetics (t1/2) | Up to approximately 7 days |
| Pharmacokinetics (AUC0-inf) | Up to approximately 7 days |
| Pharmacokinetics (AUC0-t) | Up to approximately 7 days |
| Amount of Drug Excreted Via Urine and Excrement | Up to approximately 48 hours |
Countries
China
Contacts
Primary ContactFawei Wu
Outcome results
None listed